30day FRN

79628

Federal Register / Vol. 89, No. 189 / Monday, September 30, 2024 / Notices

ddrumheller on DSK120RN23PROD with NOTICES1

confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Aging and
Neurodegeneration Integrated Review Group;
Clinical Neurodegeneration Translational
Neuroscience Study Section.
Date: October 24–25, 2024.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency, Bethesda, One
Bethesda Metro Center, Bethesda, MD 20814.
Meeting Format: In-Person Meeting.
Contact Person: Jordan M. Moore, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1002A1,
Bethesda, MD 20892, (301) 451–0293,
[email protected].
Name of Committee: Genes, Genomes, and
Genetics Integrated Review Group; Molecular
Genetics Study Section.
Date: October 24–25, 2024.
Time: 8:00 a.m. to 10:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Bethesdan Hotel, 8120
Wisconsin Avenue, Bethesda, MD 20814.
Meeting Format: In-Person Meeting.
Contact Person: Altaf Ahmad Dar, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 827–2680, [email protected]
Name of Committee: Social and
Community Influences on Health Integrated
Review Group; Social Sciences and
Population Studies B Study Section.
Date: October 24–25, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Meeting Format: In-Person Meeting.
Contact Person: Kate Fothergill, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive Room 3142,
Bethesda, MD 20892, 301–435–2309,
[email protected].
Name of Committee: Surgical Sciences,
Biomedical Imaging and Bioengineering
Integrated Review Group; Imaging
Technology Development Study Section.
Date: October 24–25, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Guo Feng Xu, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5122,
MSC 7854, Bethesda, MD 20892, (301) 237–
9870, [email protected].

VerDate Sep<11>2014

17:51 Sep 27, 2024

Jkt 262001

Name of Committee: Brain Disorders and
Clinical Neuroscience Integrated Review
Group; Brain Injury and Neurovascular
Disorders Study Section.
Date: October 24–25, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Paula Elyse Schauwecker,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5201,
Bethesda, MD 20892, 301–760–8207,
[email protected].
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Neuromodulation and Imaging of Neuronal
Circuits.
Date: October 24–25, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Pablo Miguel Blazquez
Gamez, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (301) 435–1042,
[email protected].
Name of Committee: Cardiovascular and
Respiratory Sciences Integrated Review
Group; Pulmonary Vascular Disease and
Physiology Study Section.
Date: October 24–25, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Bradley Nuss, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4142,
MSC7814 Bethesda, MD 20892, 301–451–
8754, [email protected].
Name of Committee: Brain Disorders and
Clinical Neuroscience Integrated Review
Group; Clinical Neuroplasticity and
Neurotransmitters Study Section.
Date: October 24–25, 2024.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Suzan Nadi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5217B,
MSC 7846, Bethesda, MD 20892, 301–435–
1259, [email protected].
Name of Committee: Infectious Diseases
and Immunology A Integrated Review Group;
Molecular and Structural Immunology Study
Section.
Date: October 24–25, 2024.

PO 00000

Frm 00128

Fmt 4703

Sfmt 4703

Time: 9:30 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Velasco Cimica, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–594–1760,
[email protected].
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Biophysical, Physiological,
Pharmacological and Bioengineering
Neuroscience, and Vision.
Date: October 24–25, 2024.
Time: 10:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Angela Monique Boutte,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Dr., Bethesda, MD
20892, (301) 594–0063, boutteam@
csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: September 24, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–22362 Filed 9–27–24; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Adolescent Brain &
Cognitive Development (ABCD)
StudySM—Audience Feedback Teams
(National Institute on Drug Abuse)
AGENCY:

National Institutes of Health,

HHS.
ACTION:

Notice.

In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30-days of the date of this
publication.
SUMMARY:

E:\FR\FM\30SEN1.SGM

30SEN1

79629

Federal Register / Vol. 89, No. 189 / Monday, September 30, 2024 / Notices
Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Dr. Kimberly
LeBlanc, Scientific Program Manager,
Division of Extramural Research,
National Institute on Drug Abuse, C/O
NIH Mail Center/Dock 11, 3WFN Room
09C77 MSC 6021, Gaithersburg, MD
20877 (20892 for USPS), or call non-tollfree number (301) 827–4102, or Email
your request, including your address, to:
[email protected]. Formal
requests for additional plans and
instruments must be requested in
writing.
SUPPLEMENTARY INFORMATION: This
information collection was previously
published in the Federal Register on
October 2, 2023 (88 FR 67775–67776)
and allowed 60 days for public
comment. No public comments were
received. The purpose of this notice is
to allow an additional 30 days for public
comment.
The National Institute on Drug Abuse
(NIDA), National Institutes of Health,
ADDRESSES:

may not conduct or sponsor, and the
respondent is not required to respond
to, an information collection that has
been extended, revised, or implemented
on or after October 1, 1995, unless it
displays a currently valid OMB control
number.
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection: Adolescent
Brain & Cognitive Development (ABCD)
StudySM —Audience Feedback Teams,
0925–0781, exp., date 03/31/2027,
REVISION National Institute on Drug
Abuse (NIDA), National Institutes of
Health (NIH).
Need and Use of Information
Collection: The purpose of this
information collection request is to
solicit audience feedback to improve the
data collection process for the
Adolescent Brain Cognitive
Development (ABCD) Study. Started in
2015, the ABCD Study® follows a cohort
of over 10,000 young people from preadolescence into adulthood to
understand how growing brains are
shaped by experiences and biology. To
prepare for each year’s Study data
collection, the National Institute of
Health is collecting audience feedback
on a selection of survey questions and

research protocols. Parents/caregivers
and teens who are the same age as the
study cohort members but who are not
Study participants review proposed
questions and give feedback on
questions’ clarity and acceptability.
Recommendations from these findings
help the ABCD Study team improve
their protocol for a more-successful data
collection.
Audience feedback activities include
a mix of asynchronous and scheduled,
live data collection: web-based survey
activities, virtual discussion boards,
individual interviews, and discussions
groups. Assembling a cohort of audience
feedback participants who are familiar
with the ABCD Study and participate in
multiple data collection activities
minimizes the burden required to
familiarize new participants with the
purpose of the Study and the
expectations for audience feedback.
The purpose of this revision is to
update the stimuli for which teens and
parents/caregivers are providing
feedback on wording, clarity, and areas
for improvement. This revision updates
stimuli for which feedback is complete
and includes options for new or revised
stimuli and feedback questions. Burden
levels remain unchanged.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
172.

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent

Average time
per response
(in hours)

Total annual
burden hour

Type of respondent

A—Parent/Caregiver Phone Screener and Invitation.
B—Parent/Caregiver Consent ..............................
C—Parent or Guardian Permission for Teens .....

Parents/Caregivers .......

72

1

5/60

6

Parents/Caregivers .......
Parents/Legal Guardians.
Teens ............................
Teens ............................
Teens ............................
Parents/Caregivers .......
Teens ............................

15
36

1
1

5/60
5/60

1
3

72
36
36
15
36

1
1
2
2
2

5/60
10/60
30/60
30/60
1

6
6
36
15
72

Parents/Caregivers .......
Parents/Caregivers .......
Parent/Caregivers .........

15
15
15

1
1
1

30/60
1
15/60

8
15
4

.......................................

........................

450

........................

172

D—Teen Phone Screener ....................................
E—Teen Assent or F—Teen Consent .................
G—Teen Web Survey ..........................................
H—Parent/Caregiver Web Survey ........................
I—Teen Virtual Discussion Group Guide or K—
Teen Online Bulletin Board Guide.
J—Parent/Caregiver Virtual Interview Guide ........
L—Parent/Caregiver Online Bulletin Board Guide
M—Parent/Caregiver ‘‘At-Home’’ Materials Review.
TOTAL ...........................................................
ddrumheller on DSK120RN23PROD with NOTICES1

Number of
respondents

Form name

Lanette A. Palmquist,
Project Clearance Liaison, National Institute
on Drug Abuse, National Institutes of Health.
[FR Doc. 2024–22367 Filed 9–27–24; 8:45 am]
BILLING CODE 4140–01–P

VerDate Sep<11>2014

17:51 Sep 27, 2024

Jkt 262001

PO 00000

Frm 00129

Fmt 4703

Sfmt 9990

E:\FR\FM\30SEN1.SGM

30SEN1